Ginkgo Bioworks Holdings (DNA)vsRegeneron Pharmaceuticals Inc (REGN)
DNA
Ginkgo Bioworks Holdings
$8.22
-9.17%
HEALTHCARE · Cap: $577.47M
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.33%
HEALTHCARE · Cap: $64.47B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 9754% more annual revenue ($14.92B vs $151.40M). REGN leads profitability with a 29.6% profit margin vs -201.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
DNA
Avoid29
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.5%
Fair Value
$8.70
Current Price
$8.22
$0.48 premium
Margin of Safety
+54.7%
Fair Value
$1346.63
Current Price
$635.45
$711.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -68.7% — below average capital efficiency
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
DNA profiles as a turnaround stock while REGN is a growth play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.80 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 29/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a leader in synthetic biology, specializing in advanced genetic engineering to develop tailor-made bioengineered organisms for diverse applications, including pharmaceuticals, agriculture, and industrial biotech. Its cutting-edge platform enhances cellular design for efficient manufacturing processes, positioning the company to meet pressing global challenges such as climate change and food security. Ginkgo's unique capabilities and focus on sustainable biotechnology solutions not only address growing market demands for bio-based alternatives but also signify a compelling growth trajectory, underscoring its potential to drive transformative impact across multiple industries.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?